OpenAI 收购 Orchestra Bio，用 AI 智能体追踪药物研发项目
OpenAI bought Orchestra Bio, whose AI agents track drug programs.
OpenAI 收购了 Orchestra Bio，后者的 AI 智能体用于追踪药物研发项目。Orchestra 的智能体监控研究与时间线，当生产批次失败时，它们会梳理哪些试验受影响，并比较应对方案供项目负责人选择；此前 OpenAI 的 GPT-Rosalind 负责生物学与化学推理，Rosalind Workbench 负责连接模型与实验室工具和数据。文章还提到，Anthropic 在 4 月以约 4 亿美元股票收购 Coefficient Bio，两家实验室都在收购专业生物学团队，而药物研发从靶点到美国获批平均仍需 10 到 15 年。
推荐理由
AI 评分 63
这条消息把 OpenAI 收购 Orchestra Bio 与 Anthropic 收购 Coefficient Bio 放在一起，呈现两家实验室在生物医药方向的布局差异。
主题
正文
当前显示原文，中文全文译文尚未就绪。
OpenAI bought Orchestra Bio, whose AI agents track drug programs.
Until now, Rosalind covered the science: GPT-Rosalind reasons through biology and chemistry, while Rosalind Workbench links models to lab tools and data.
Orchestra targets a different bottleneck, the coordination work that spreads a drug program across departments, contractors and disconnected software.
Its agents monitor studies and timelines, so when a manufacturing batch fails, they map which trials slip and compare responses for program leaders to choose.
Anthropic paid roughly $400M in stock for Coefficient Bio in April, so both labs are now buying specialist biology teams.
Development still averages 10 to 15 years from target to US approval, a clock largely set by trial biology and regulators.